Zannas Anthony S, Kim Jun H, West Anne E
Deparment of Neurobiology, Duke University Medical Center, Durham, NC, 27710, USA.
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 27710, USA.
Psychopharmacology (Berl). 2017 Mar;234(6):913-923. doi: 10.1007/s00213-017-4527-7. Epub 2017 Jan 23.
Phosphorylation of the methyl DNA-binding protein MeCP2 at Ser421 (pMeCP2-S421) is induced in corticolimbic brain regions during exposure to drugs of abuse and modulates reward-driven behaviors. However, whether pMeCP2-S421 is also involved in behavioral adaptations to aversive drugs is unknown.
Our goal was to establish the role and regulation of pMeCP2-S421 in corticolimbic brain regions of mice upon acute treatment with the kappa opioid receptor agonist U50488 and during the expression of U50488-induced conditioned place aversion (CPA).
pMeCP2-S421 levels were measured in the nucleus accumbens (NAc), prelimbic cortex, infralimbic cortex (ILC), and basolateral amygdala (BLA) of male mice after intraperitoneal administration of U50488 and upon the expression of U50488-induced CPA. Fos was measured as marker of neural activity in the same brain regions. U50488-induced CPA and Fos levels were compared between knockin (KI) mice that lack pMeCP2-S421 and their wild-type (WT) littermates.
U50488 administration acutely induced pMeCP2-S421 and Fos selectively in the NAc but did not alter MeCP2 levels in any brain region. U50488-induced CPA was associated with decreased pMeCP2-S421 in the ILC and BLA and induced Fos in the BLA. MeCP2 KI mice showed CPA indistinguishable from their WT littermates, but they also showed less BLA Fos induction upon CPA.
These data are the first to show that pMeCP2-S421 is induced in the brain acutely after U50488 administration but not upon U50488-induced CPA. Although pMeCP2-S421 is not required for U50488-induced CPA, this phosphorylation event may contribute to molecular plasticities in brain regions that govern aversive behaviors.
在暴露于滥用药物期间,甲基化DNA结合蛋白MeCP2在丝氨酸421位点的磷酸化(pMeCP2-S421)在皮质边缘脑区被诱导,并调节奖赏驱动行为。然而,pMeCP2-S421是否也参与对厌恶性药物的行为适应尚不清楚。
我们的目标是确定在给予κ阿片受体激动剂U50488急性处理后以及在U50488诱导的条件性位置厌恶(CPA)表达过程中,pMeCP2-S421在小鼠皮质边缘脑区中的作用和调节机制。
在雄性小鼠腹腔注射U50488后以及在U50488诱导的CPA表达时,测量伏隔核(NAc)、前边缘皮层、边缘下皮层(ILC)和基底外侧杏仁核(BLA)中pMeCP2-S421的水平。测量Fos作为相同脑区神经活动的标志物。比较缺乏pMeCP2-S421的敲入(KI)小鼠与其野生型(WT)同窝小鼠之间U50488诱导的CPA和Fos水平。
给予U50488后急性诱导NAc中pMeCP2-S421和Fos的表达,但未改变任何脑区中MeCP2的水平。U50488诱导的CPA与ILC和BLA中pMeCP2-S421的降低以及BLA中Fos的诱导有关。MeCP2 KI小鼠表现出与野生型同窝小鼠难以区分的CPA,但在CPA时它们的BLA Fos诱导也较少。
这些数据首次表明,给予U50488后pMeCP2-S421在脑中被急性诱导,但在U50488诱导的CPA时未被诱导。虽然U50488诱导的CPA不需要pMeCP2-S421,但这种磷酸化事件可能有助于调节厌恶性行为的脑区中的分子可塑性。